The approval process for hyperthermic intraoperative intraperitoneal chemotherapy

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Paul H Sugarbaker, L Clarke

Abstract

To clarify the requirements for Food and Drug Administration approval in the United States for hyperthermic intraoperative intraperitoneal chemotherapy administration. Also, to review the status of the approval process in Europe. The obstacles to be overcome for approval by the Food and Drug Administration for a new drug approval and for a new device approval were reviewed. Drugs approved in the past were examined for their potential for current application in this technology. The likelihood that the approval of a heater circulator along with the approval for specific chemotherapy agents for heated intraoperative intraperitoneal chemotherapy was judged to be remote. Rather, the continued use of "homemade heater circulators" and the off-label use of appropriate chemotherapy agents augmented by heat will continue to be the standard of care. The European community currently has several heater circulators approved for hyperthermic intraoperative intraperitoneal chemotherapy administration. These devices have been specifically approved for oncologic indications. Continued research and development of heated intraoperative intraperitoneal chemotherapy is necessary. As the requirement for prevention and treatment of the peritoneal surf...Continue Reading

References

Nov 26, 2002·The British Journal of Surgery·D G JayneF Seow-Choen
Oct 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vic J VerwaalFrans A N Zoetmulder
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O GlehenP Rat

❮ Previous
Next ❯

Citations

Apr 15, 2014·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·A CaneparoM De Simone
Oct 2, 2012·Surgical Oncology Clinics of North America·Santiago González-MorenoGloria Ortega-Pérez
Dec 5, 2009·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·P Ortega-DeballonP Rat
Apr 6, 2007·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·M GuerbetJ Lubrano
May 8, 2014·The Journal of Surgical Research·Monika Posaric-BaudenBobby Tingstedt
Mar 27, 2019·Pleura and Peritoneum·Martin Hübner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Related Papers

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
K SchmidH Drexler
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
L González-BayónG Ortega-Pérez
© 2022 Meta ULC. All rights reserved